Therapeutic | Ianalumab |
Target | TNFRSF13C |
Heavy Chain | QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYQWVPKIGVFDSWGQGTLVTVSS |
Light Chain | DIVLTQSPATLSLSPGERATLSCRASQFILPEYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFYSSPLTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II/III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | POTELLIGENT Technology |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | H. Lee Moffitt Cancer Center and Research Institute, MorphoSys, Novartis |
Conditions Approved | na |
Conditions Active | Autoimmune hepatitis, Idiopathic pulmonary fibrosis, Multiple sclerosis, Pemphigus vulgaris, Rheumatoid arthritis, Sjogren's syndrome, Systemic lupus erythematosus, Chronic lymphocytic leukaemia |
Conditions Discontinued | na |
Notes |